Featured Article
"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"
While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.
Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”
As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.
Read Full Article Now
You May Also Like
Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol
Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol
Evaluating Dietary Strategies as Adjunctive Interventions in Inflammatory Skin Disease As patients increasingly seek non-pharmacologic interventions to support their psoriasis treatment, interest in dietary modifications has surged. However, clinical guidance…
The State of Sunscreens in the US: Caveat Emptor
The State of Sunscreens in the US: Caveat Emptor
From JDD's Vault: The State of Sunscreens in the US: Caveat Emptor With the FDA’s groundbreaking June 2026 approval of a new sunscreen ingredient, bemotrizinol (also called BEMT or Tinosorb…
JDD Re:View With Dr. Beer
JDD Re:View With Dr. Beer
Beyond the Skin: Navigating Psoriasis Treatment and Patient Burden Management of psoriasis can often involve trialing several medications, extensive patient counseling, and working with insurance companies to get the optimal…
